UBS Group Boosts Hologic (NASDAQ:HOLX) Price Target to $90.00

Hologic (NASDAQ:HOLX) had its target price boosted by UBS Group from $84.00 to $90.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a neutral rating on the medical equipment provider’s stock.

A number of other brokerages have also weighed in on HOLX. Royal Bank of Canada boosted their target price on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday. Raymond James boosted their price objective on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday. Mizuho dropped their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday. Leerink Partners decreased their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Finally, JPMorgan Chase & Co. raised their price target on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Hologic has a consensus rating of “Moderate Buy” and an average target price of $89.25.

Hologic Price Performance

Shares of HOLX opened at $78.76 on Tuesday. Hologic has a fifty-two week low of $66.93 and a fifty-two week high of $84.67. The firm’s 50-day simple moving average is $80.97 and its two-hundred day simple moving average is $78.15. The stock has a market cap of $18.29 billion, a PE ratio of 23.65, a price-to-earnings-growth ratio of 3.03 and a beta of 0.98. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. The firm had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 20.11% and a net margin of 19.59%. Hologic’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.89 EPS. Analysts anticipate that Hologic will post 4.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hologic

Hedge funds have recently made changes to their positions in the company. Wolff Wiese Magana LLC bought a new stake in shares of Hologic in the 3rd quarter valued at about $25,000. Innealta Capital LLC purchased a new position in Hologic during the second quarter valued at approximately $25,000. iA Global Asset Management Inc. purchased a new position in Hologic during the first quarter valued at approximately $37,000. First Horizon Advisors Inc. raised its stake in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares in the last quarter. Finally, Sunbelt Securities Inc. purchased a new stake in Hologic during the second quarter worth $37,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.